文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

先天性角化不良患者造血干细胞移植的结局

Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
PubMed 文献 · Br J Haematol · 2018-07-09

该研究纳入迄今最大队列的94例先天性角化不良(DC)患者,分析造血干细胞移植(HSCT)后结局。HSCT后3年总生存率(OS)为66%、无事件生存率(EFS)为62%。多因素分析显示年龄小于20岁及配型相合供者移植者结局更好,非清髓预处理方案似乎最可取。

要点

  • HSCT后3年OS为66%,EFS为62%。
  • 年龄小于20岁及配型相合供者移植者结局更好。
  • 非清髓预处理方案似乎最可取。

核心结论

  • 根据现有数据,DC患者在进行性骨髓衰竭时适合行HSCT,而存在移植前器官损害者应仔细评估。
  • 应鼓励进一步研究HSCT以外的替代治疗。

研究设计与样本

  • 研究收集了迄今最大队列的94例DC患者HSCT结局数据。

主要发现

  • HSCT后3年OS为66%,EFS为62%。
  • 多因素分析显示年龄小于20岁和配型相合供者移植的患者结局更好。
  • OS和EFS曲线随时间推移呈下降趋势。
  • 早期致死事件为感染,而器官损害和第二肿瘤在之后出现,甚至移植后十年。
  • 非清髓预处理方案似乎最可取。

关键数值与推荐

  • 3年OS为66%,3年EFS为62%。

临床怎么用

  • 作者认为,DC患者在进行性骨髓衰竭时适合行HSCT,而存在移植前器官损害者应仔细评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dyskeratosis congenita (DC) is a genetic multisystem disorder with frequent involvement of the bone marrow. Haematopoietic stem cell transplantation (HSCT) is the only definitive cure to restore haematopoiesis, even though it cannot correct other organ dysfunctions. We collected data on the outcome of HSCT in the largest cohort of DC (n = 94) patients ever studied. Overall survival (OS) and event-free survival (EFS) at 3 years after HSCT were 66% and 62%, respectively. Multivariate analysis showed better outcomes in patients aged less than 20 years and in patients transplanted from a matched, rather than a mismatched, donor. OS and EFS curves tended to decline over time. Early lethal events were infections, whereas organ damage and secondary malignancies appeared afterwards, even a decade after HSCT. A non-myeloablative conditioning regimen appeared to be most advisable. Organ impairment present before HSCT seemed to favour the development of chronic graft-versus-host disease and T-B immune deficiency appeared to enhance pulmonary fibrosis. According to the present data, HSCT in DC is indicated in cases of progressive marrow failure, whereas in patients with pre-existing organ damage, this should be carefully evaluated. Further efforts to investigate treatment alternatives to HSCT should be encouraged.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Fioredda F, Iacobelli S, Korthof ET, et al. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol. 2018. PMID: 29984823. doi:10.1111/bjh.15495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。